Nadunolimab is under clinical development by Cantargia and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData, Phase II drugs for Metastatic Biliary Tract Cancer have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nadunolimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nadunolimab overview
Nadunolimab (CAN-04) is under development for the treatment solid tumors including urothelial cancer, liver cancer, myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), esophageal cancer, head and neck cancer, metastatic non-small cell lung cancer, extrahepatic cholangiocarcinoma, gallbladder cancer, pancreatic ductal adenocarcinoma, triple negative breast cancer, colorectal cancer, colon cancer, metastatic biliary tract cancer, metastatic pancreatic cancer, squamous non-small cell lung cancer, other solid tumors and neuropathy. It is administered by intravenous route. The drug candidate acts by targeting leukemic stem cells by binding to the IL1-RAP receptor. It was also under development for acute lymphocytic leukemia, and chronic myelocytic leukemia, urothelial cancer, head and neck cancer, bladder cancer, malignant melanoma.
Cantargia overview
Cantargia is a biotechnology company that develops antibody-based cancer treatments. The company’s product candidate CAN04 is used for the treatment of cancers including non-small cell lung cancer, triple-negative breast cancer and pancreatic cancer; and CAN10 targets myocarditis. It utilizes cell surface receptors as a target to develop a novel antibody-based therapy for treating chronic myeloid leukemia and other forms of leukemia. Cantargia provides therapies for the treatment of hematological malignancies that use the expression of cell surface receptors on hematopoietic stem cells. The company also develops antibody therapeutics to eradicate leukemia disease-causing stem cells. Cantargia is headquartered in Lund, Sweden.
For a complete picture of Nadunolimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
